《新股消息》中国抗体制药-B(03681.HK)明起招股 入场费2,909.02元(更正)
中国抗体制药-B(03681.HK)公布招股详情,计划以每股7.6元至9.6元发行约1.82亿股,当中10%於香港公开发售,集资最多17.48亿元,每手300股入场费约2,909.02元。中金公司及东方证券为其联席保荐人。
该公司将於明日(31日)起至下周二(11月5日)招股,预期11月12日上市。是次引入两名基石投资者云南白药(000538.SZ)及瑞捷软件科技,合共投资6,000万美元,设六个月禁售期,其中云南白药认购5,000万美元等值股份。
以招股价中位数每股8.6元计,集资净额为约14.61亿元,所得约50%用於研发及商业化其核心产品;40%用於建设苏州生产基地;以及10%用作营运资金等。
董事会主席兼首席执行官梁瑞安表示,未来将继续研发用於治疗免疫性疾病的新型药物,令产品组合多元化,并尽快商业化旗舰产品SM03,除海口生产基地外,亦计划兴建苏州生产基地,以应付未来商业化所需要的生产需求。
(更正:2019-10-30 18:01:14 《新股消息》中国抗体制药-B
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.